Boosting with variant-matched vaccines: an opportunity to win the race against Omicron

作     者：Jiayu Wang Tianxia Lan Qiu Sun 

作者机构：State Key Laboratory of BiotherapyCancer CenterWest China HospitalSichuan University and Collaborative Innovation Center for Biotherapy610041 ChengduChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2022年第7卷第7期

页      面：2126-2127页

核心收录：

学科分类：0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学] 

主　　题：vaccines impaired al. 

摘      要：Recently,Baoling Ying et *** a study in Cell that investigated whether using BA.1-matched or historical mRNA vaccine as a booster could enhance the protection against Omicron infection.1 In this study,the team evaluated the anti-Omicron efficacies of these two types of vaccines as primary(two-dose)immunization series or thirddose boosters in mice,respectively(Fig.1).Many of the current outbreaks of COVID-19 around the world have been shown to be driven by the Omicron variant of SARSCoV-2.2 Although vaccination remains one of the most efficient approaches to containing the pandemic,amino acid substitutions,deletions,and insertions in the spike protein of the Omicron variant have substantially impaired the efficacy of most licensed vaccines.3 Hence,more effective vaccines or vaccination strategies against Omicron are urgently needed.